XML 23 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Pay vs Performance Disclosure - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Pay vs Performance Disclosure        
Pay vs Performance Disclosure, Table
Value of Initial Fixed $100 Investment Based On:
Year
Summary Compensation Table Total for PEO ($)(1)
Compensation Actually Paid to PEO ($)(2)
Average Summary Compensation Table Total for Non-PEO NEOs ($)(3)
Average Compensation Actually Paid to Non-PEO NEOs ($)(4)
Total Shareholder Return ($)(5)
Peer Group Total Shareholder Return ($)(5)
GAAP Net Income (millions) ($)(6)
Net Product Sales
(millions) ($)(7)
(a)(b)(c)(d)(e)(f)(g)(h)(i)
2023$15,750,812$12,335,515$6,286,290$5,262,182$122.58$118.87$249.7$1,860.6
2022$11,902,527$21,886,517$5,200,614$11,398,982$111.46$111.66$154.5$1,440.9
2021$14,081,412$4,496,176$6,429,791$3,012,565$79.48$125.33$89.6$1,090.1
2020$13,880,632$8,176,596$6,522,476$4,030,852$89.45$126.13$407.3$994.1
 
      
Named Executive Officers, Footnote The dollar amounts reported in column (b) are the amounts of total compensation reported for Kevin C. Gorman, Ph.D. (PEO) for each corresponding year in the “Total” column of the Summary Compensation Table. The dollar amounts reported in column (d) represent the average of the amounts reported for the Company’s Non-PEO NEOs as a group in the “Total” column of the Summary Compensation Table in each applicable year. The names of each of the Non-PEO NEOs included for purposes of calculating the average amounts in each applicable year are as follows: (i) for 2023, Matthew C. Abernethy, Kyle W. Gano, Ph.D., Jude Onyia, Ph.D., and Eiry W. Roberts, M.D.; (ii) for 2022, Matthew C. Abernethy, Kyle W. Gano, Ph.D., Darin M. Lippoldt, and Eiry W. Roberts, M.D.; (iii) for 2021, Matthew C. Abernethy, Eric Benevich, Jude Onyia, Ph.D., and Eiry W. Roberts, M.D.; (iv) for 2020, Matthew C. Abernethy, Eric Benevich, Kyle W. Gano, Ph.D., and Eiry W. Roberts, M.D.      
PEO Total Compensation Amount $ 15,750,812 $ 11,902,527 $ 14,081,412 $ 13,880,632
PEO Actually Paid Compensation Amount $ 12,335,515 21,886,517 4,496,176 8,176,596
Adjustment To PEO Compensation, Footnote The dollar amounts reported in column (c) represent the amount of CAP for Dr. Gorman, as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not reflect the actual amount of compensation earned by or paid to Dr. Gorman during the applicable year. In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to Dr. Gorman’s total reported compensation for 2023 to determine the CAP:
2023
Total Compensation for Covered Fiscal Year ("FY") from Summary Compensation Table
$15,750,812 
Deduct: Amounts Reported in "Stock Awards" & "Option Awards" Columns
13,700,176 
Add: Year End Fair Value of Equity Awards Granted During the Covered FY that Remain Outstanding and Unvested as of Last Day of the Covered FY9,092,870 
Add: Change in Fair Value from the end of the Prior FY to the end of the Covered FY
(101,013)
Add: Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Covered FY
1,334,539 
Add: Change in Fair Value as of the Vesting Date of Equity Awards Granted in Prior FY that Vested in the Covered FY
(41,517)
Add: Fair Value at the End of the Prior FY of Equity Awards that Failed to Meet Vesting Conditions in the Covered FY
— 
Add: Value of Dividends or other Earnings Paid on Stock or Option Awards not Otherwise Reflected in Fair Value or Total Compensation— 
Compensation Actually Paid (as defined by SEC rule)$12,335,515 
      
Non-PEO NEO Average Total Compensation Amount $ 6,286,290 5,200,614 6,429,791 6,522,476
Non-PEO NEO Average Compensation Actually Paid Amount $ 5,262,182 11,398,982 3,012,565 4,030,852
Adjustment to Non-PEO NEO Compensation Footnote The dollar amounts reported in column (e) represent the average amount of CAP to the Non-PEO NEOs, as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not reflect the actual average amount of compensation earned by or paid to the NEOs as a group (excluding Dr. Gorman) during the applicable year. In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to average total reported compensation for the Non-PEO NEOs for each year to determine the CAP, using the same methodology described above in Note 2:
2023
Total Compensation for Covered FY from Summary Compensation Table
$6,286,290 
Deduct: Amounts Reported in "Stock Awards" & "Option Awards" Columns
5,187,621 
Add: Year End Fair Value of Equity Awards Granted During the Covered FY that Remain Outstanding and Unvested as of Last Day of the Covered FY4,212,074 
Add: Change in Fair Value from the end of the Prior FY to the end of the Covered FY
(68,838)
Add: Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Covered FY
618,180 
Add: Change in Fair Value as of the Vesting Date of Equity Awards Granted in Prior FY that Vested in the Covered FY
(597,903)
Add: Fair Value at the End of the Prior FY of Equity Awards that Failed to Meet Vesting Conditions in the Covered FY
— 
Add: Value of Dividends or other Earnings Paid on Stock or Option Awards not Otherwise Reflected in Fair Value or Total Compensation— 
Compensation Actually Paid (as defined by SEC rule)$5,262,182 
      
Equity Valuation Assumption Difference, Footnote
The assumptions used in calculating the fair value of the equity awards did not differ in any material respect from the assumptions used to calculate the grant date fair value of the awards as reported in the Summary Compensation Table, except that the fair value calculations of (i) the options granted on or between February 7, 2019 and February 13, 2023 used an estimated term between 1.37 years and 7.04 years in FY 2023, as compared to an estimated term of 6.0 to 6.5 years used to calculate the grant date fair value of such awards, and (ii) the PRSUs assumed payout multipliers at current expectations, which range from 0% to 158% across different grant years and metrics, in each case as compared to the grant date fair value calculations which assumed a payout at target.
      
Compensation Actually Paid vs. Total Shareholder Return 5692      
Compensation Actually Paid vs. Net Income 5693      
Compensation Actually Paid vs. Company Selected Measure
5695
      
Tabular List, Table Net Product Sales
•Non-GAAP Operating Expense
•Non-GAAP Operating Income
•Pipeline Progression
•Regulatory Advancement
•Total Prescriptions (TRx)
      
Total Shareholder Return Amount $ 122.58 111.46 79.48 89.45
Peer Group Total Shareholder Return Amount 118.87 111.66 125.33 126.13
Net Income (Loss) $ 249,700,000 $ 154,500,000 $ 89,600,000 $ 407,300,000
Company Selected Measure Amount 1,860,600,000 1,440,900,000 1,090,100,000 994,100,000
PEO Name Kevin C. Gorman, Ph.D      
Additional 402(v) Disclosure The dollar amounts reflect the cumulative Total Shareholder Return (TSR) of our common stock (column (f)) and the Peer Group (column (g)) for the measurement periods beginning on December 31, 2019 and ending on December 31 of each of 2023, 2022, 2021 and 2020, respectively, calculated in accordance with Item 201(e) of Regulation S-K. “Peer Group” represents the NASDAQ Biotechnology Index, which the Company has identified as its peer group for purposes of Item 402(v) and which is used by the Company for purposes of compliance with Item 201(e) of Regulation S-K. The dollar amounts reported in column (h) represent net income reflected in the Company’s audited financial statements for the applicable fiscal year.As required by Item 402(v) of Regulation S-K, we have determined that Net Product Sales is the Company-Selected Measure. Dollar amounts reported for INGREZZA net product sales, which represent nearly all of the Company's total net product sales, are reflected in the Company's audited financial statements for the applicable fiscal year.      
Measure:: 1        
Pay vs Performance Disclosure        
Name •Net Product Sales      
Measure:: 2        
Pay vs Performance Disclosure        
Name •Non-GAAP Operating Expense      
Measure:: 3        
Pay vs Performance Disclosure        
Name •Non-GAAP Operating Income      
Measure:: 4        
Pay vs Performance Disclosure        
Name •Pipeline Progression      
Measure:: 5        
Pay vs Performance Disclosure        
Name •Regulatory Advancement      
Measure:: 6        
Pay vs Performance Disclosure        
Name •Total Prescriptions (TRx)      
PEO | Adjustment To Grant Date Fair Value Of Equity Awards Granted During Year [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount $ 13,700,176      
PEO | Adjustment To Year End Fair Value Of Equity Awards [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 9,092,870      
PEO | Adjustment To Year Over Year Change In Fair Value Of Outstanding And Unvested Equity Awards [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount (101,013)      
PEO | Adjustment To Fair Value As Of Vesting Date Of Equity Awards Granted And Vested In The Year [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 1,334,539      
PEO | Adjustment To Year Over Year Change In Fair Value Of Equity Awards Granted In Prior Years That Vested In The Year [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount (41,517)      
PEO | Adjustment To Fair Value At The End Of The Prior Year Of Equity Awards That Failed To Meet Vesting Conditions In The Year [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 0      
PEO | Adjustment To Value Of Dividends Or Other Earnings Paid On Stock Or Option Awards Not Otherwise Reflected In Fair Value Or Total Compensation [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 0      
Non-PEO NEO | Adjustment To Grant Date Fair Value Of Equity Awards Granted During Year [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 5,187,621      
Non-PEO NEO | Adjustment To Year End Fair Value Of Equity Awards [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 4,212,074      
Non-PEO NEO | Adjustment To Year Over Year Change In Fair Value Of Outstanding And Unvested Equity Awards [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount (68,838)      
Non-PEO NEO | Adjustment To Fair Value As Of Vesting Date Of Equity Awards Granted And Vested In The Year [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 618,180      
Non-PEO NEO | Adjustment To Year Over Year Change In Fair Value Of Equity Awards Granted In Prior Years That Vested In The Year [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount (597,903)      
Non-PEO NEO | Adjustment To Fair Value At The End Of The Prior Year Of Equity Awards That Failed To Meet Vesting Conditions In The Year [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 0      
Non-PEO NEO | Adjustment To Value Of Dividends Or Other Earnings Paid On Stock Or Option Awards Not Otherwise Reflected In Fair Value Or Total Compensation [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount $ 0